Cellectis Management

Management criteria checks 4/4

Cellectis' CEO is Andre Choulika, appointed in Jan 1999, has a tenure of 25.25 years. total yearly compensation is $744.02K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth €2.37M. The average tenure of the management team and the board of directors is 3.7 years and 7.1 years respectively.

Key information

Andre Choulika

Chief executive officer

US$744.0k

Total compensation

CEO salary percentage	100.0%
CEO tenure	25.3yrs
CEO ownership	1.4%
Management average tenure	3.7yrs
Board average tenure	7.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andre Choulika's remuneration changed compared to Cellectis's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$72m
Jun 30 2023	n/a	n/a	-US$77m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$744k	US$744k	-US$91m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$99m
Dec 31 2021	US$879k	US$879k	-US$86m
Sep 30 2021	n/a	n/a	-US$129m
Jun 30 2021	n/a	n/a	-US$121m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$1m	US$1m	-US$37m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$67m
Dec 31 2019	US$1m	US$1m	-US$102m

Compensation vs Market: Andre's total compensation ($USD744.02K) is about average for companies of similar size in the German market ($USD705.27K).

Compensation vs Earnings: Andre's compensation has been consistent with company performance over the past year.

CEO

Andre Choulika (58 yo)

25.3yrs

Tenure

US$744,016

Compensation

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. He is the Director of Cellectis...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andre Choulika	Co-Founder	25.3yrs	US$744.02k	1.39% $ 2.4m
David j. Sourdive	Deputy CEO	no data	US$528.92k	0.39% $ 666.4k
Bing Wang	Chief Financial Officer	2.2yrs	no data	0% $ 0
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	2.3yrs	no data	no data
Jean Epinat	Chief Technological Officer	no data	no data	no data
Philippe Duchateau	Chief Scientific Officer	12.3yrs	no data	0.054% $ 91.9k
Stephan Reynier	Chief Regulatory & Pharmaceutical Compliance Officer	no data	no data	0.021% $ 36.0k
Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	11.3yrs	no data	0.036% $ 61.9k
Pascalyne Wilson	Director of Communications	no data	no data	no data
Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	3.4yrs	no data	0.0098% $ 16.7k
Arthur Stril	Chief Business Officer	3.6yrs	no data	0.0055% $ 9.4k
Steven Doares	Senior VP of US Manufacturing & Site Head of the Raleigh	3.8yrs	no data	0.0090% $ 15.4k

3.7yrs

Average Tenure

54yo

Average Age

Experienced Management: ZVA's management team is considered experienced (3.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andre Choulika	Co-Founder	25.3yrs	US$744.02k	1.39% $ 2.4m
David j. Sourdive	Deputy CEO	24.3yrs	US$528.92k	0.39% $ 666.4k
Jean-Pierre Garnier	Independent Non-Executive Chairman	3.4yrs	US$127.44k	0% $ 0
Laurent Arthaud	Director	12.5yrs	no data	no data
Pierre Bastid	Director	12.5yrs	US$98.80k	0.078% $ 133.0k
Rainer Boehm	Director	6.8yrs	US$87.58k	0% $ 0
Dietger Niederwieser	Member of Clinical Advisory Board	7.1yrs	no data	no data
Kanti Rai	Member of Clinical Advisory Board	7.3yrs	no data	no data
Catherine Bollard	Member of Clinical Advisory Board	7.1yrs	no data	no data
Ola Landgren	Member of Clinical Advisory Board	7.1yrs	no data	no data
Marcela Maus	Member of Clinical Advisory Board	7.1yrs	no data	no data
Stephan Grupp	Member of Clinical Advisory Board	5.6yrs	no data	no data

7.1yrs

Average Tenure

59yo

Average Age

Experienced Board: ZVA's board of directors are considered experienced (7.1 years average tenure).

Cellectis Management

Management criteria checks 4/4

Key information

Recent management updates

Cellectis S.A. Announces Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Recent updates

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Less than half of directors are independent

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.09 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Full year 2022 earnings released: US$1.99 loss per share (vs US$2.55 loss in FY 2021)

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Now 26% undervalued after recent price drop

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Now 24% undervalued

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.28 loss in 1Q 2021)

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.76 loss in 2Q 2020)

Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing and Technologies

First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.47 profit in 1Q 2020)

Cellectis S.A. Announces Preliminary Results from its Phase 1 Balli-01 Clinical Study of Ucart22 in Adults with R/R B-All Presented in Oral Session At 2020 Ash Annual Meeting

Full year 2020 earnings released: US$1.91 loss per share (vs US$2.41 loss in FY 2019)

Revenue beats expectations

Cellectis S.A. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day low: €18.20

Cytovia Therapeutics, Inc. and Cellectis Enter into Strategic Research and Development Collaboration

New 90-day high: €27.45

New 90-day high: €25.85

New 90-day high: €25.65

New 90-day high: €18.66

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma

Cellectis Appoints Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Revenue misses expectations

Third quarter 2020 earnings released: US$0.71 loss per share